Curr Probl Cancer 2016 Mar - Aug
Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.
Related Questions
OS benefit was limited to patients with endocrine sensitivity, defined as either a documented clinical benefit (CR, PR, or SD for ≥24 weeks) f...
New answer by Medical Oncologist at Private Practice and Digital Health (November 14, 2018)
I will generally give a trial of first line endocrine therapy with an AI if endocrine-sensitive disease, and reserve Paloma-3 regimen to second line. Endocrine sensitivity can...
AI+ CK4/6 inhibitor? Fulvestrant + CK4/6 inhibitor? AI + fulvestrant? AI + fulvestrant + CK4/6 inhibitor?
New answer by Medical Oncologist at University of California Irvine Medical Center (May 1, 2019)
S0226 is the only phase-III study to show overall survival advantage in first-line, largely endocrine-naïve patient population, currently. FACT required patient...
New comment by Medical Oncologist at Valley Med Onc ( December 10, 2023)
Dr. @Rubin brings up a very important point. We are exposing a tremendous number of women to the increased toxicity and cost of combination therapy without knowing if upfront ...